NEW YORK (GenomeWeb News) – Response Genetics has signed a deal with Roche Diagnostics to support the development of a cancer assay.

The Los Angeles-based firm said today that it had licensed to Roche non-exclusive rights to use its PCR analysis technology to assess human epidermal growth factor type 2 gene expression. A test that can accurately measure HER2 expression could assist physicians with treatment decisions for patients with certain cancers in tissues such as breast.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.